Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
12 mai 2021 07h30 HE
|
Voyager Therapeutics, Inc.
Findings to be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy Data demonstrate durable expression in CNS and may represent a new single-dose therapeutic...
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates
11 mai 2021 07h30 HE
|
Voyager Therapeutics, Inc.
Data to be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene...
Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
10 mai 2021 07h30 HE
|
Voyager Therapeutics, Inc.
- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference,...
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting
28 avr. 2021 08h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
26 avr. 2021 08h00 HE
|
Voyager Therapeutics, Inc.
One-Time Gene Therapy to be Evaluated in Patients with Early Huntington’s Disease Initiation of VYTAL Phase 1/2 Clinical Trial at Multiple Sites Expected this Year CAMBRIDGE, Mass., April 26, 2021 ...
Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
25 févr. 2021 16h01 HE
|
Voyager Therapeutics, Inc.
Expects to Provide Complete Response to FDA Requests on IND Application for VY-HTT01 for Huntington’s Disease in the First Half of 2021Continues to Progress Pipeline and Platform Activities with...
Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference
18 févr. 2021 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
02 févr. 2021 16h01 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of the...
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 janv. 2021 16h03 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe...
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
22 déc. 2020 16h17 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences...